<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589457</url>
  </required_header>
  <id_info>
    <org_study_id>163BE15028</org_study_id>
    <nct_id>NCT02589457</nct_id>
  </id_info>
  <brief_title>Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet</brief_title>
  <official_title>A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics of CKD-390(Tenofovir
      Disoproxil Aspartate) and Viread® tablet(Tenofovir Disoproxil Fumarate) in healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and
      Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet
      (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Tenofovir</measure>
    <time_frame>0(Pre-dose) up to 72hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0(Pre-dose) up to 72hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 day, 2 day, 3 day, 4 day, 15 day 16 day, 17 day 18 day, 25 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>0(Pre-dose) up to 72hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β</measure>
    <time_frame>0(Pre-dose) up to 72hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance/F</measure>
    <time_frame>0(Pre-dose) up to 72hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiography</measure>
    <time_frame>1 day, 2 day, 3 day, 4 day, 15 day 16 day, 17 day 18 day, 25 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>1 day, 2 day, 3 day, 4 day, 15 day 16 day, 17 day 18 day, 25 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>1 day, 2 day, 3 day, 4 day, 15 day 16 day, 17 day 18 day, 25 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>1 day, 2 day, 3 day, 4 day, 15 day 16 day, 17 day 18 day, 25 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Viread® tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-390</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-390</intervention_name>
    <description>Tenofovir Disoproxil Aspartate 1T PO</description>
    <arm_group_label>CKD-390</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viread® tablet</intervention_name>
    <description>Tenofovir Disoproxil Fumarate 1T PO</description>
    <arm_group_label>Viread® tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer in the age of 19-45

          2. Body weight ≥ 55kg and in the range of calculated Ideal Body Weight ± 20%

          3. Subject without a hereditary problems, chronic disease and morbid symptom

          4. Subject who sign on an informed consent form willingly

        Exclusion Criteria:

          1. Clinically significant disease with hepatobiliary, nephrological, gastrointestinal,
             respiratory, hepato-oncological, endocrine, urogenital, neurologic, psychiatric,
             musculoskeletal, immune, otorhinolaryngological, cardiovascular system

          2. Gastrointestinal disease(Crohn's disease, ulcer, acute/chronic pancreatitis) or
             gastrointestinal surgery(except for appendectomy or herniotomy)

          3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the
             history of drugs or additives

          4. Galactose intolerance, Lapp lactase deficiency or Glucose-galactose malabsorption

          5. Sitting systolic blood pressure &gt; 140mmHg or &lt; 100mmHg, sitting diastolic blood
             pressure ≥ 90mmHg or &lt; 60mmHg, pulse ≥ 100 beats per minute

          6. Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin &gt; 2 x upper
             limit of normal range

          7. Have the result of Creatinine clearance is less than 50mL/min(Cockcroft-Gault equation
             applicable)

          8. The history of drug abuse or drug abuse showed a positive for urine drug test

          9. Subject treated metabolizing enzyme inducers or inhibitors including barbiturates
             within 1 month

         10. Subject treated ethical the counter or herbal medicine within 2 weeks,
             over-the-counter or vitamin within 1 week

         11. Taking drugs have received any other investigational drug within 3 months prior to the
             first dosing

         12. Whole blood donation within 2 months prior to the first dosing or component blood
             donation within 1 months prior to the first dosing or blood transfusion within 1 month

         13. Continuously taking excessive alcohol (&gt; 21 units/week; 1 unit = 10g of pure alcohol)
             or cannot stop drinking from 24 hours before admission to discharge

         14. Cigarette &gt; 10 cigarettes a day on average for recent 3 months

         15. Subjects with planning of dental treatment (tooth extraction, endodontic treatment
             etc.) and any surgery (aesthetic operation, laser in-situ keratomileusis, laser
             assisted sub-epithelial keratomileusis etc.) from signed on an informed consent form
             to post-study visit

         16. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B virus, HIV-1 infection</keyword>
  <keyword>Healthy Male Volunteer</keyword>
  <keyword>Tenofovir Disoproxil Fumarate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

